B+
Bull case
25%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
ZNTL
ZentalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+76.2
Score
AI commentary
Primary-source tone is constructive because March and May 2026 company filings confirmed dose selection, ASPENOVA initiation, and cash runway into late 2027, but the evidence base is still mostly company-controlled and filing-led. There is no trusted recent-news packet, no analyst-revision detail, and no usable social-coverage signal here, so the setup remains a cautious monitoring view rather than a confirmed rerating thesis.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystCash runway limits immediate financing pressureMedium impact
Zentalis reported $211.8 million of cash, cash equivalents and marketable securities as of March 31, 2026 and said that runway extends into late 2027, which supports execution through key ovarian-cancer milestones but does not remove burn risk for a precommercial biotech [#SEC-8K-2026-05-12].
2026-12-31eventASPENOVA execution can de-risk the registration pathHigh impact
Management said ASPENOVA, the Phase 3 confirmatory trial in Cyclin E1-positive PROC, has been initiated with first patient dosed and is intended to support full approval and ex-US registrations, so visible enrollment and operational progress through 2H 2026 would help validate the broader approval strategy [#SEC-8K-2026-05-12].
2026-12-31catalystDENALI Part 2 topline remains the decisive rerating eventHigh impact
The company continues to guide to a DENALI Phase 2 topline readout by year-end 2026, with potential relevance to an accelerated approval pathway subject to data outcomes and FDA feedback; for ZNTL this remains the core binary value driver [#SEC-8K-2026-05-12][#SEC-8K-2026-03-26][#PR-EARNINGS-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology